晚期重症肺癌的诊疗策略  

Diagnosis and treatment strategy for advanced severe lung cancer

作　　者：谢展鸿[1] 周承志[1] 秦茵茵[1] 欧阳铭[1] 李时悦[1] 陈荣昌[1] 钟南山[1] XIE Zhan-hong;ZHOU Cheng-zhi;QIN Yin-yin;OUYANGMing;LI Shi-yue;CHEN Rong-chang;ZHONG Nan-shan(Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China)

机构地区：[1]呼吸疾病国家重点实验室呼吸疾病国家临床研究中心广州医科大学附属第一医院广州呼吸健康研究院,广东广州510120

出　　处：《中国实用内科杂志》2019年第5期416-419,共4页Chinese Journal of Practical Internal Medicine

基　　金：呼吸疾病国家重点实验室自主课题(SKIRDQN-201720);呼吸疾病国家重点实验室开放课题(SKIRDOP-2018011;广东省高水平大学临床培育项目(2018-2022)

摘　　要：晚期重症肺癌不是指终末期肺癌,而是指因疾病本身各种相关原因、或者在应用抗肿瘤药物后所导致的患者PS评分阶段性的处于2～4分,但是存在极大可能性能够从现有的系统性抗肿瘤治疗手段中获益的的ⅢB、ⅢC及Ⅳ期肺癌患者。诊疗策略上强调尽可能实现微创化动态监测靶点及疗效;必要时通过呼吸支持治疗来实现抗肿瘤治疗,尽可能将每一个药物的作用发挥尽致,尽可能将每一个对患者有用的药都用到;具体治疗理念包括联合、交替、全局观、PS评分、药物的升降级、癌肺同治。Advanced severe lung cancer means the stage IIIB, IIIC, and IV lung cancer patients with a PS score of 2 to 4 points due to various related causes of lung cancer itself or the complication of anti-tumor drugs, with a high probability of benefiting from the existing systemic anti-tumor treatments. The diagnosis and treatment strategies emphasize the implementation of minimally invasive dynamic monitoring mutation targets and curative effects. Every drug that is useful to the patient should be used as possible, and making the best use of every drug as possible with the help of respiratory support therapy. Specific treatment concepts include combination therapy,alternating medication, paying equal attention to systemic therapy and local therapy, PS score assessment, upgrading and downgrading of drug use, and simultaneous treatment of cancer and lung itself.

关 键 词：晚期肺癌 重症 诊疗策略 

分 类 号：R734[医药卫生—肿瘤]